From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick, as it just reached a key level of support. PSTX's 50-day simple moving average crossed above its ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...

Poseida Therapeutics is a biopharmaceutical company specializing in cell and gene therapies for cancer and genetic conditions. The company's proprietary gene editing and delivery platforms show ...

The average one-year price target for Poseida Therapeutics (NASDAQ:PSTX) has been revised to 14.28 / share. This is an increase of 14.29% from the prior estimate of 12.50 dated November 26, 2023. The ...

Poseida Therapeutics reported strong Q2 2023 revenue growth of 641.22% YoY, beating estimates by $14.93 million. Astellas Pharma's $50 million investment in Poseida's cancer cell therapy is a positive ...

Have you been paying attention to shares of Poseida Therapeutics, Inc. (PSTX)? Shares have been on the move with the stock up 282.9% over the past month. The stock hit a new 52-week high of $9.41 in ...